We are live on ! Find out more
ZYNE

Zynerba Pharmaceuticals, Inc
ZYNE

Delisted

ZYNE was delisted on the 10th of October, 2023.

Back to rankings

50 hedge funds and large institutions have $4.23M invested in Zynerba Pharmaceuticals, Inc in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

640% more call options, than puts

Call options by funds: $37K | Put options by funds: $5K

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

19% less funds holding

Funds holding: 62 → 50 (-12)

47% less capital invested

Capital invested by funds: $7.97M → $4.23M (-$3.74M)

86% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 14

Holders
50
Holders Change
-12
Holders Change %
-19.35%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
13
Reduced
16
Closed
14
Calls
$37K
Puts
$5K
Net Calls
+$32K
Net Calls Change
-$24K

Top Buyers

Rank Fund Capital Flow
1
ECM
ExodusPoint Capital Management
New York
+$12.4K
2
UBS Group
UBS Group
Switzerland
+$9.6K
3
Morgan Stanley
Morgan Stanley
New York
+$8.01K
4
ETC
Exchange Traded Concepts
Oklahoma
+$7.33K
5
BWP
Bernardo Wealth Planning
Pennsylvania
+$5.14K

Top Sellers

Rank Fund Capital Flow
1
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$660K
2
EMG
ETF Managers Group
New Jersey
-$474K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$236K
4
Renaissance Technologies
Renaissance Technologies
New York
-$171K
5
GCP
GSA Capital Partners
United Kingdom
-$96K
Name Holding Trade Value Shares
Change 		Change in
Stake
ETC
26
Exchange Traded Concepts
Oklahoma
$9.93K +$7.33K +11,562 +161%
Citadel Advisors
27
Citadel Advisors
Florida
$9.26K -$64.9K -102,364 -85%
TRCT
28
Tower Research Capital (TRC)
New York
$8K -$8.95K -14,113 -48%
KWMG
29
King Wealth Management Group
Florida
$8K – – –
KFI
30
Key Financial Inc
Pennsylvania
$5.49K – – –
NFSG
31
Newbridge Financial Services Group
Florida
$3.22K – – –
Group One Trading
32
Group One Trading
Illinois
$3.21K +$663 +1,045 +21%
FCMT
33
Founders Capital Management (Texas)
Texas
$1K -$634 -1,000 -33%
Rockefeller Capital Management
34
Rockefeller Capital Management
New York
$1K – – –
Simplex Trading
35
Simplex Trading
Illinois
$1K +$2.33K +3,667 New
CFGS
36
Concourse Financial Group Securities
Alabama
$265 – – –
SIS
37
Sound Income Strategies
Florida
$186 – – –
HNB
38
Huntington National Bank
Ohio
$115 – – –
Bank of America
39
Bank of America
North Carolina
$81 +$32 +51 +50%
HI
40
Harbour Investments
Wisconsin
$53 – – –
KTC
41
Kistler-Tiffany Companies
Pennsylvania
$53 – – –
Citigroup
42
Citigroup
New York
$53 +$63 +100 New
HPC
43
HM Payson & Co
Maine
$26 – – –
Northwestern Mutual Wealth Management
44
Northwestern Mutual Wealth Management
Wisconsin
$2 -$159 -250 -99%
GIA
45
GHP Investment Advisors
Colorado
$1 – – –
LC
46
Lindbrook Capital
California
$1 – – –
Mirae Asset Global Investments
47
Mirae Asset Global Investments
South Korea
– -$660K -901,835 Closed
GCP
48
GSA Capital Partners
United Kingdom
– -$96K -131,036 Closed
VIA
49
Vident Investment Advisory
Georgia
– -$77K -105,398 Closed
HF
50
HRT Financial
New York
– -$23K -32,642 Closed
1
2
3

ZYNE Hedge Fund Activity: Q4 2022 in Review

50 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2022, worth a combined $4.23M — down 47% from $7.97M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ZYNE and 2 opened new positions — a net loss of 12 holders — while 16 trimmed existing stakes and 13 added.

The largest buyer was ExodusPoint Capital Management, adding an estimated $12.4K. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $660K sold.

  • 50 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2022, down from 62 in Q3 2022.
  • Funds reported $4.23M of Zynerba Pharmaceuticals, Inc stock for Q4 2022, down 47% quarter-over-quarter.
  • 2 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2022 and 14 closed out, a net change of -12 holders.
  • The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2022 was ExodusPoint Capital Management, an estimated $12.4K added.
  • The largest Zynerba Pharmaceuticals, Inc seller in Q4 2022 was Mirae Asset Global Investments, an estimated $660K sold.

Based on aggregated 13F filings for Q4 2022.